These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21691743)

  • 1. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis.
    Poormoghim H; Moradi Lakeh M; Mohammadipour M; Sodagari F; Toofaninjed N
    Rheumatol Int; 2012 Aug; 32(8):2431-44. PubMed ID: 21691743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.
    Volkmann ER; Tashkin DP; Sim M; Li N; Khanna D; Roth MD; Clements PJ; Hoffmann-Vold AM; Furst DE; Kim G; Goldin J; Elashoff RM
    J Rheumatol; 2019 Oct; 46(10):1316-1325. PubMed ID: 30770517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.
    Beretta L; Caronni M; Raimondi M; Ponti A; Viscuso T; Origgi L; Scorza R
    Clin Rheumatol; 2007 Feb; 26(2):168-72. PubMed ID: 16614793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
    Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
    Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
    Ma X; Tang R; Luo M; Zeng Z; Shi Y; Tang B; Xiao R
    Clin Rheumatol; 2021 Aug; 40(8):3185-3193. PubMed ID: 34080081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.
    Theodore AC; Tseng CH; Li N; Elashoff RM; Tashkin DP
    Chest; 2012 Sep; 142(3):614-621. PubMed ID: 22156609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.
    Nannini C; West CP; Erwin PJ; Matteson EL
    Arthritis Res Ther; 2008; 10(5):R124. PubMed ID: 18937831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.
    Panopoulos ST; Bournia VK; Trakada G; Giavri I; Kostopoulos C; Sfikakis PP
    Lung; 2013 Oct; 191(5):483-9. PubMed ID: 23925736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study.
    Poormoghim H; Rezaei N; Sheidaie Z; Almasi AR; Moradi-Lakeh M; Almasi S; Andalib E
    Rheumatol Int; 2014 Dec; 34(12):1691-9. PubMed ID: 24801572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
    Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
    Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
    Yilmaz N; Can M; Kocakaya D; Karakurt S; Yavuz S
    Int J Rheum Dis; 2014 Nov; 17(8):923-8. PubMed ID: 24864029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis.
    Zheng JN; Yang QR; Zhu GQ; Pan L; Xia JX; Wang Q
    Mod Rheumatol; 2020 Jul; 30(4):687-695. PubMed ID: 31269839
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
    Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
    Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease.
    Caron M; Hoa S; Hudson M; Schwartzman K; Steele R
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29769294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study.
    Štorkánová H; Oreská S; Špiritović M; Heřmánková B; Bubová K; Komarc M; Pavelka K; Vencovský J; Distler JHW; Šenolt L; Bečvář R; Tomčík M
    Sci Rep; 2021 Jan; 11(1):1. PubMed ID: 33414495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide versus placebo in scleroderma lung disease.
    Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
    N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.
    Gerbino AJ; Goss CH; Molitor JA
    Chest; 2008 Feb; 133(2):455-60. PubMed ID: 18071023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
    Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
    Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.